Characterizing antibody-secreting cells one at a time

| September 18, 2017

article image
Antibodies are a major component of the immune response and a powerful tool in research and disease therapeutics. But characterizing antibody-secreting cells in terms of their antibody production rate and the specificity and affinity of the antibodies they make has not been possible at the single cell level. In a recent paper in Nature Biotechnology, Jean Baudry and colleagues report a method that enables massively parallel characterization of single IgG-secreting cells.

Spotlight

Mitotech LLC

Mitotech LLC is the hub company of biotech project "Skulachev ions". The company goal is to develop and market set of innovative pharmaceuticals based on new type of biologically active compounds - mitochondrially targeted antioxidants SkQ. Investors of the company is RUSNANO (Russian state corporation of nanotechnologies - www.rusnano.com) and Rostok Group (private foundation - www.grostok.ru).

OTHER ARTICLES

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Defense biotech research looks to eliminate bacteria causing traveler’s diarrhea, reduce jet lag duration

Article | April 9, 2020

World traveler‘s will rejoice at the idea of a seemingly magical device that would guarantee they never suffer from the all-too-familiar stomach issues that come from traveling internationally while reducing jet lag at the same time. But it’s not just privileged globetrotters that would benefit from a device that eliminates the bacteria associated with the so-called Montezuma’s Revenge. In 2016, more than 230,000 children around the world died from some of the same types of bacteria as those that cause traveler’s diarrhea, and the bacteria mainly come from unsafe “drinking water, poor sanitation and malnutrition,” according to Oxford University’s Our World In Data portal. On Monday, DARPA announced it was researching an “implantable or ingestible bioelectronic carrier” that would eliminate the five major bacteria associated with traveler’s diarrhea.

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Biotech: Finding The DNA For Success

Article | April 3, 2020

The integration of artificial intelligence within life sciences is making drug discovery and development more innovative, less labor intensive and more cost-effective, says Deloitte’s annual global outlook. According to Deloitte’s 2020 Global Life Sciences Outlook, the biotech sector is at an inflection point. To prepare for the future and remain relevant in the ever-evolving business landscape, biopharma and medtech organizations will be looking for new ways to create value and new metrics to make sense of today’s wealth of data, the report overview says. As data-driven technologies provide biopharma and medtech organizations with treasure troves of information, and automation takes over some mundane tasks, new talent models are emerging based on purpose and meaning. The integration of artificial intelligence (AI) and machine learning approaches within life sciences is making drug discovery and development more innovative, time-effective and cost-effective, the Deloitte report states.

Read More

Spotlight

Mitotech LLC

Mitotech LLC is the hub company of biotech project "Skulachev ions". The company goal is to develop and market set of innovative pharmaceuticals based on new type of biologically active compounds - mitochondrially targeted antioxidants SkQ. Investors of the company is RUSNANO (Russian state corporation of nanotechnologies - www.rusnano.com) and Rostok Group (private foundation - www.grostok.ru).

Events